Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis

Psoriasis (PsO) is a chronic inflammatory dermatosis that often presents with erythematous, sharply demarcated lesions. Although psoriasis is primarily a dermatological disease, its immune-mediated pathogenesis produces systemic effects and is closely associated with various comorbid conditions such...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Elena Campione, Nikkia Zarabian, Terenzio Cosio, Cristiana Borselli, Fabio Artosi, Riccardo Cont, Roberto Sorge, Ruslana Gaeta Shumak, Gaetana Costanza, Antonia Rivieccio, Roberta Gaziano, Luca Bianchi
Format:	Article
Language:	English
Published:	MDPI AG 2024-07-01
Subjects:	apremilast psoriasis comorbidities metabolic syndrome PDE4-inhibitor
Online Access:	https://www.mdpi.com/1424-8247/17/8/989